Description
Loxonin® Tablets 60mg / ロキソニン錠60mg
Oral NSAID. Propionic acid derivative (prodrug) indicated for anti-inflammatory, analgesic, and antipyretic use in adults. Manufactured in Japan by Daiichi Sankyo Co., Ltd.
Key information
| Generic name | Loxoprofen Sodium Hydrate (JP) |
|---|---|
| Brand name | Loxonin® Tablets 60mg |
| Strength | 60 mg loxoprofen (as anhydrous) per tablet (= 68.1 mg as hydrate) |
| Dosage form | Uncoated tablet with score line, very pale red, round (Ø 9.1 mm) |
| Identification code | SANKYO 157 |
| ATC class | M01AE (Propionic acid derivatives) |
| JP standard commodity code | 871149 |
| Approval number | 22100AMX01321 (Japan, MHLW) |
| Manufacturer | Daiichi Sankyo Co., Ltd., Tokyo, Japan |
Indications
Anti-inflammatory and analgesic use for:
- Rheumatoid arthritis
- Osteoarthritis
- Lumbago
- Shoulder periarthritis
- Cervicobrachial syndrome
- Toothache
- Post-operative, post-traumatic, and post-extraction pain/inflammation
Antipyretic and analgesic use for:
- Acute upper respiratory tract inflammation (including acute bronchitis with URTI)
Dosage and administration
Chronic indications (RA, OA, lumbago, periarthritis, cervicobrachial syndrome, toothache):
Adults: 60 mg orally, three times daily after meals. Adjust per age and symptoms. Avoid administration on empty stomach.
Acute / PRN use (post-op, post-trauma, post-extraction, fever, URTI):
Adults: 60 mg as a single dose. 60–120 mg may be used. Maximum 2 doses per day, up to 180 mg daily. Adjust per age and symptoms.
Concomitant use with other NSAIDs is not recommended.
Contraindications
Do not use in patients with:
- Peptic ulcer
- Severe blood dyscrasias
- Severe hepatic impairment
- Severe renal impairment
- Severe cardiac insufficiency
- Hypersensitivity to loxoprofen
- Aspirin-induced asthma (or history thereof)
- Late pregnancy
Warnings and precautions
NSAID therapy is symptomatic, not curative. Monitor patients for: gastrointestinal ulceration/bleeding, renal impairment, hepatic impairment, blood disorders (including agranulocytosis, hemolytic anemia, aplastic anemia, thrombocytopenia), cardiovascular thromboembolic events (MI, stroke), hypersensitivity reactions including SJS/TEN, interstitial pneumonia, and aseptic meningitis. See package insert for full list of adverse reactions and drug interactions (warfarin, Factor Xa inhibitors, sulfonylureas, quinolones, methotrexate, lithium, thiazides, ACE inhibitors/ARBs).
Storage
Room temperature (1–30°C). Protect from light and moisture.
Shelf life
3 years from date of manufacture.
Package
- PTP blister: 100 tablets (10 × 10), 1,000 tablets (10 × 100), 3,150 tablets (21 × 150)
- Bulk bottle (with desiccant): 1,000 tablets
B2B wholesale
- Unit price: Contact us for quotation
- MOQ: 100 boxes (tentative — to be finalized per order)
- Incoterms: FOB Osaka / CIF negotiable
- Lead time: 2–4 weeks from order confirmation
- Packaging options: PTP blister or bulk bottle available
Regulatory documents
📄 Official Japanese Package Insert (PDF)
📄 Certificate of Analysis — available upon request
📄 CPP / Export certificate — available upon request
Disclaimer: Product information is based on the Japanese package insert (revised March 2025, 4th edition). This document is for informational purposes only and does not constitute medical advice. Please consult the official package insert for complete prescribing information.
Reviews
There are no reviews yet.